GlassScriptPhysician profile
Scott W Mandel
NPI 1043254568
$3,391.72
in general payments reported to CMS, 2019-2025
24 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $375 · 2021: $1,000 · 2022: $778 · 2023: $210 · 2024: $162 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484 · Education: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.44 |
| Education | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.09 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $377.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $354.08 | 2020-2025 | |
| Novo Nordisk INC | $285.72 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $236.14 | 2019-2025 | Repatha |
| Pfizer INC. | $231.28 | 2019-2025 | |
| Astellas Pharma US INC | $208.41 | 2019-2023 | |
| Esperion Therapeutics, INC. | $190.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $186.86 | 2020-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $158.11 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $146.17 | 2019-2022 | |
| Medtronic, INC. | $141.66 | 2021-2023 | Micra |
| Merck Sharp & Dohme LLC | $93.64 | 2019-2022 | |
| Encore Medical, LP | $84.18 | 2021 | |
| Abbvie INC. | $59.64 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $49.52 | 2019-2020 | |
| Althera Pharmaceuticals LLC | $37.94 | 2021 | |
| Coala Life INC | $23.73 | 2021 | |
| Abbott Laboratories | $18.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.08 | 2019 | |
| Boston Scientific Corporation | $13.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2022 | |
| Lundbeck LLC | $12.66 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $5.53 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.